ABVC BioPharma, Inc. has signed a term sheet to advance a partnership with Zhonghui United Technology Group Co., Ltd. to develop a large-scale health and wellness base in Chengdu, China. The planned partnership involves ABVC transferring common shares to Zhonghui in exchange for a twenty percent ownership of Zhonghui’s property near Chengdu, valued at $37 million, and a piece of land in the same area. The partnership aims to establish an integrated platform for collaborations between researchers and industry leaders in the healthcare sector.
ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it has signed a term sheet to advance a partnership with Zhonghui United Technology (Zhonghui) Group Co., Ltd. and its affiliated enterprises. The partnership contemplates a planned acquisition of real estate assets via an equity transfer, estimated at $7.4 million, all to advance the development of a large-scale health and wellness base in Chengdu, China.
The planned partnership aims to establish an integrated platform to facilitate collaborations between researchers and industry leaders. ABVC intends to transfer common shares to Zhonghui at $20 per share in consideration for a twenty percent ownership of Zhonghui’s property near Chengdu, China, estimated at $37 million by a third-party valuation company and a piece of land Zhonghui currently owns in that same area.
“We are pleased to have executed the term sheet with Zhonghui, a wholly owned corporation established in 2020 with total assets of $4.4 billion, annual revenue of $4.2 billion, and a net profit of $757 million,” said Uttam Patil, Ph.D. CEO of ABVC. “With this initiative, we will work towards developing a large health and wellness base to establish a comprehensive facility that provides a wide range of services. The integrated platform will help facilitate collaboration between industry, academia, and research. We strive for revitalization by promoting innovation, knowledge exchange, and sustainable development in rural areas around Chengdu. Strong partnerships with leading institutions and our expertise in Oncology/Hematology, Neurology, and Ophthalmology enable us to expand globally.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Completing definitive agreements with Zhonghui and acquiring the real estate assets is subject to due diligence, negotiation of definitive agreements between the parties, and relevant regulatory approvals.
Source: BioSpace
